氨溴索辅助治疗小儿重症肺炎临床疗效观察

Clinical Observation of Ambroxol in the Treatment of Severe Pneumonia in Children

目的探讨氨溴索辅助治疗小儿重症肺炎临床治疗效果。方法选取该院2015年1月—2017年1月收治的80例重症肺炎患儿作为研究的对象,采用随机数字表的方法 ,分为两组,观察组40例患儿采取的是氨溴索的辅助治疗方法;对照组40例患儿采取的是常规的治疗方式,比较两组患儿的临床疗效、临床症状改善消失时间、肺功能指标以及炎性介质水平。结果观察组与对照组患儿临床疗效分别为95.00%、77.50%有显著差异(χ~2=-12.911 7,P<0.05)。观察组患儿肺部湿啰音、气促、咳嗽、发热改善消失时间分别为(4.8±1.2)d、(3.3±1.4)d、(4.4±1.4)d、(3.5±1.7)d,对照组分别为(5.4±1.3)d、(4.2±1.2)d、(5.5±1.6)d、(5.4±2.0)d。观察组明显快于对照组,差异有统计学意义(t=4.149 9、4.087 0、4.272 3、4.578 0,P<0.05)。观察组患儿的达峰时间比、潮气量分别为(43.23±3.45)%、(74.56±5.62)mL,显著高于对照组(36.89±3.17)%、(67.68±5.00)mL,呼吸频率(36.43±3.81)次/min,显著低于对照组(41.23±3.91)次/min,以上数据均有统计学意义(t=9.375 2、6.336 7、6.0915,P<0.05)。结论氨溴索辅助治疗小儿重症肺炎疗效显著,可有效改善临床症状、肺功能、炎症反应,且安全性高,值得临床推广。

Objective To investigate the clinical effect of ambroxol in the treatment of severe pneumonia in children.Methods Eighty children with severe pneumonia admitted to our hospital from January 2015 to January 2017 were enrolled in the study.They were randomly divided into two groups.The observation group was treated with 40 children,auxiliary treatment of ambroxol;40 patients in the control group were treated with conventional treatment,and the clinical efficacy,clinical symptom improvement disappearance time,lung function index and inflammatory mediator level were compared between the two groups.Results The clinical efficacy of the observation group and the control group were 95.00% and 77.50%,respectively(χ^2=-12.9117,P<0.05).The disappearance time of lung wetness,shortness of breath,cough and fever in the observation group was(4.8±1.2)d、(3.3±1.4)d、(4.4±1.4)d、(3.5±1.7)d,respectively,and the control group was(5.4±1.3)d、(4.2±1.2)d、(5.5±1.6)d、(5.4±2.0)d.The observation group was significantly faster than the control group,and the difference was statistically significant(t=4.149 9,4.087 0,4.272 3,4.578 0,P<0.05).The peak time ratio and tidal volume of the observation group were(43.23±3.45)% and(74.56±5.62)mL,which were significantly higher than the control group(36.89±3.17)%,(67.68±5.00)mL,and the respiratory rate was(36.43±3.81)time/min,significantly lower than the control group(41.23±3.91)times/min),the above data were statistically significant(t=9.375 2,6.336 7,6.091 5,P<0.05).Conclusion Ambroxol is effective in the treatment of severe pneumonia in children.It can effectively improve clinical symptoms,lung function and inflammatory response,and it is safe and worthy of clinical promotion.